Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden

Samankaltaisia teoksia

• The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34(+) progenitor cells
  Tekijä: Mohr, Brigitte, et al.
  Julkaistu: (2009)
• Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring
  Tekijä: Oelschlaegel, Uta, et al.
  Julkaistu: (2015)
• Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
  Tekijä: Sockel, Katja, et al.
  Julkaistu: (2012)
• Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
  Tekijä: Schönefeldt, C, et al.
  Julkaistu: (2013)
• Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse
  Tekijä: Sockel, Katja, et al.
  Julkaistu: (2011)